Hemodynamics, fluids & transfusion
Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial
Authors' conclusion
This exploratory post-hoc analysis of phase 3 clinical trial data suggests a potential benefit of AT II introduction at lower doses of other vasopressor agents.
Study context
- Population
- Patients with vasodilatory shock hypotensive (MAP 55–70 mmHg) despite standard vasopressors at norepinephrine-equivalent dose (NED) > 0.2 µg/kg/min; grouped by low (≤ 0.25 µg/kg/min; n = 104) or high (> 0.25 µg/kg/min; n = 217) NED at study drug initiation
- Participants
- 321 patients
- Comparison
- AT II vs Placebo
- Primary endpoint
- Difference in 28-day survival between AT II and placebo in those with baseline NED ≤ 0.25 µg/kg/min
- Follow-up
- 28 days
Methodological detailsexploratory post-hoc analysis, subgroup analysis
- Exploratory post-hoc analysis
- Subgroup analysis
Primary result
As reported in the abstract
28-day survival, adjusted for severity of illness, by baseline NED subgroup
- Low-NED subgroup: AT II half as likely to die at 28 days vs placebo
- High-NED subgroup: no differences in 28-day survival between AT II and placebo
- Exploratory post-hoc analysis
- Adjusted for severity of illness
Further findings
Baseline NED, low-NED subgroup · similar
P = 0.45
Baseline NED, high-NED subgroup · similar
P = 0.75
Safety
Serious adverse events
- Less frequent with AT II vs placebo in low-NED subgroup (not statistically significant); comparable in high-NED subgroups
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial. Crit Care. Published 5 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →